Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine：a phase I clinical trial
Background Rotavirus infections, prevalent in human populations, are caused mostly by group A viruses. Immunization against rotaviruses in infancy is currently the most effective and economical strategy to prevent rotavirus infection. This study evaluated the safety of a novel hexavalent rotavirus v...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Taylor & Francis Group
2021-07-01
|
| Reeks: | Human Vaccines & Immunotherapeutics |
| Onderwerpen: | |
| Online toegang: | http://dx.doi.org/10.1080/21645515.2020.1861874 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|